Cancer

Title
A Clinical Trial of Dasatinib in Participants with Unresectable Locally Advanced Vulvovaginal Melanomas
Trial Number
204199021512
Number of Participants
110
Principal Investigator

Joseph Clark

M.D.
Hematology/Oncology
Professor
Eligibility

Participants must be 18 years of age or older and have an ECOG performance status of 0 or 1, have a histological or cytological confirmed melanoma that is metastatic or unresectable. They also must have measurable disease (at least one measurable lesion) as defined by RECIST criteria.

Participants must also have a history of melanoma of one of the following subtypes:
- Acral (as defined as occurring on the palms, soles or subungual sites)
- Melanoma arising from the vagina and/or vulva
- Melanoma arising on other mucosal surface (not vagina or vulva)

Purpose

The purpose of this study is to find out what effects, good and/or bad, dasatinib has on you and your melanoma cancer.

Enrollment

(708) 327-3221

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.